Vancouver, British Columbia--(Newsfile Corp. - December 31, 2019) - The Yield Growth Corp. (CSE: BOSS) (OTCQB: BOSQF) (FSE:YG3) will host an investor conference call and webcast, on January 7th, 2020 at 1pm Eastern Standard Time, featuring a live presentation by Yield Growth CEO and Co-Founder, Penny White.





Webcast: Tuesday, January 7, 2020 at 10AM PST / 1PM EST



To view an enhanced version of this graphic, please visit:

https://orders.newsfilecorp.com/files/6377/51082_PR_WEB_Webcast_MagicMushrooms.jpg

Yield Growth invites shareholders and potential investors to attend the webcast event where the company will provide an overview of what's ahead for 2020, including exciting opportunities in functional mushrooms and psychedelic research with the launch of Yield Growth subsidiary Flourish Mushroom Labs Inc. and its line of edible mushroom products.

Webcast Event Details:

Date: Tuesday, January 7, 2020

Time: 10AM PST / 1PM EST

Register for free here: https://www.moneyworksmagazine.com/yield-growth-corp-investor-webcast-rsvp/

An April 2019 report by Mordor Intelligence states that the global functional food market is forecasted to reach US $34.3 billion by 2024, growing at a CAGR of 8.04% between 2019 and 2024.

Although magic mushrooms remain illegal in most jurisdictions, a softening on regulatory stances may be in the works to allow potentially therapeutic compounds to help millions of people in dire need of alternatives to today's prescription drugs. Through its Flourish subsidiary, Yield Growth is quickly moving to the forefront of a trend that could disrupt the $4.2 trillion wellness market.

According to their website, the John Hopkins Centre for Psychedelic & Consciousness Research is focusing on how psychedelics affect behavior, mood, cognition, brain function, and biological markers of health. Through studies, scientists are investigating the effectiveness of psilocybin as a new therapy for a myriad of ailments including opioid addiction, Alzheimer's disease, post-traumatic stress disorder (PTSD), post-treatment Lyme disease syndrome, anorexia nervosa and alcohol use in people with major depression.

The researchers hope to create precision medicine treatments tailored to the specific needs of individual patients.

According to the Psychedelic Science Review, the global market for conventional antidepressants alone was valued at $13.7 billion in 2016, and is projected to grow to $15.9 billion by 2023. A study conducted by the Beckley/Imperial Research Programme has provided clinical evidence for the efficacy of psilocybin-assisted psychotherapy to treat depression, even in cases where all other treatments have failed.

Flourish Mushroom Labs has filed a patent to protect the invention that compounds in magic mushrooms can result in weight loss by reducing food cravings, counteracting compulsive overeating, and aiding in improving quality of diet by altering food choices. The pending patent covers the use of microdose administration of psilocin/psilocybin to have the additional weight loss effect of increasing metabolism, which, combined with a decrease in food cravings or compulsive overeating, or altering food choices to less calorie dense foods, could result in substantial and beneficial weight loss and treatment of illnesses associated with obesity.

Story continues